These progestins are selective progesterone receptor (PR) agonists that inhibit ovulation, follicle development, growth of endometrial cells and cytokine production, which leads to inhibition of estrogen production and efficacy for treatment of estrogen-dependent endometrial cancer. The gene discussed is PGR; the disease is endometrial cancer.